p53 abnormalities in splenic lymphoma with villous lymphocytes

Blood

Volumn 97, Issue 11, 2001, Pages 3552-3558

  Gruszka Westwood, Alicja M ^a,b   Hamoudi, Rifat A ^a,b   Matutes, Estella ^a,b   Tuset, Esperanza ^a,b   Catovsky, Daniel ^a,b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CHROMOSOME 17Q; DNA BINDING; FEMALE; FLOW CYTOMETRY; GENE DELETION; GENE LOSS; HUMAN; IMMUNOPHENOTYPING; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SEQUENCE ANALYSIS; SURVIVAL;

EID: 0035383803     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.11.3552     Document Type: Article

References (39)

1. Matutes E, Morilla R, Owusu Ankomah K, Houlihan A, Catovsky D. The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood. 1994;83:1558-1562.
2. Isaacson PG, Matutes E, Burke M, Catovsky D. The histopathology of splenic lymphoma with villous lymphocytes. Blood. 1994;84:3828-3834.
3. Mulligan SP, Matutes E, Dearden C, Catovsky D. Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol. 1991;78:206-209.
4. Parry-Jones N, Matutes E, Swansbury GJ, Catovsky D. Prognostic markers in patients with splenic lymphoma with villous lymphocytes. British Society for Haematology Annual Meeting. Br J Haematol. Bournemouth, United Kingdom: Blackwell Sciences; 2000:73.
5. Oscier DG, Matutes E, Gardiner A, et al. Cytogenetic studies in splenic lymphoma with villous lymphocytes. Br J Haematol. 1993;85:487-491.
6. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000;77:81-137.
7. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
8. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878.
9. Ahnen DJ, Feigl P, Quan G, et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study. Cancer Res. 1998;58:1149- 1158.
10. Osada M, Ishioka C, Ichinohasama R, et al. Influence of p53 mutation on pathological grade, but not prognosis of non-Hodgkin's lymphoma. Anti-Cancer Drug Design. 1999;14:107-114.
11. Korkolopoulou P, Angelopoulou MK, Kontopidou F, et al. Prognostic implications of proliferating cell nuclear antigen (PCNA), AgNORs and P53 in non-Hodgkin's lymphomas. Leuk Lymphoma. 1998;30:625-636.
12. Navaratnam S, Williams GJ, Rubinger M, et al. Expression of p53 predicts treatment failure in aggressive non-Hodgkin's lymphomas. Leuk Lymphoma. 1998;29:139-144.
13. Wilson WH, Teruya-Feldstein J, Fest T, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood. 1997;89:601-609.
14. Moller MB, Gerdes AM, Skjodt K, Mortensen LS, Pedersen NT. Disrupted p53 function as predictor of treatment failure and poor prognosis in B- and T-cell non-Hodgkin's lymphoma. Clin Cancer Res. 1999;5:1085-1091.
15. Chen PM, Chiou TJ, Hsieh RK, et al. p53 gene mutations and rearrangements in non-Hodgkin's lymphoma. Cancer. 1999;85:718-724.
16. Du M, Peng H, Singh N, Isaacson PG, Pan L. The accumulation of p53 abnormalities is associated with progression of mucosa-associated lymphoid tissue lymphoma. Blood. 1995;86:4587-4593.
17. Hernandez L, Fest T, Cazorla M, et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood. 1996;87:3351-3359.
18. Koduru PR, Raju K, Vadmal V, et al. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood. 1997;90:4078-4091.
19. Clodi K, Younes A, Goodacre A, et al. Analysis of p53 gene deletions in patients with non-Hodgkin's lymphoma by dual-colour fluorescence in-situ hybridization. Br J Haematol. 1997;98:913-921.
20. Imamura J, Miyoshi I, Koeffler HP. p53 in hematologic malignancies. Blood. 1994;84:2412-2421.
21. Matutes E, Owusu Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640-1645.
22. Matutes E, Morilla R, Owusu Ankomah K, et al. The immunophenotype of hairy cell leukemia (HCL): proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leuk Lymphoma. 1994; 14(suppl 1):57-61.
23. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods. 1992;151:237-244.
24. Cheng J, Haas M. Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines. Mol Cell Biol. 1990;10:5502-5509.
25. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics. 1989;5:874-879.
26. Lens D, De Schouwer PJ, Hamoudi RA, et al. p53 abnormalities in B-cell prolymphocytic leukemia. Blood. 1997;89:2015-2023.
27. Oka T, Sarker AB, Teramoto N, Yoshino T, Akagi T. p53 protein expression in non-Hodgkin's lymphomas is infrequently related to p53 gene mutations. Pathol Int. 1998;48:15-21.
28. Lepelley P, Preudhomme C, Vanrumbeke M, et al. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia. 1994;8: 1342-1349.
29. Roemer K. Mutant p53: gain-of-function oncoproteins and wild-type p53 inactivators. Biol Chem. 1999;380:879-887.
30. Nakai H, Misawa S, Toguchida J, Yandell DW, Ishizaki K. Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p. Cancer Res. 1992;52:6588-6593.
31. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex; understanding tumorigenic mutations [see comments]. Science. 1994;265:346-355.
32. Hainaut P, Hernandez T, Robinson A, et al. IARC database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools. Nucleic Acids Res. 1998;26:205-213.
33. Drach J, Ackermann J, Fritz E, et al. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood. 1998;92:802-809.
34. Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and nonresponse to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85:1580-1589.
35. Callet Bauchu E, Salles G, Gazzo S, et al. Translocations involving the short arm of chromosome 17 in chronic B-lymphoid disorders: frequent occurrence of dicentric rearrangements and possible association with adverse outcome. Leukemia. 1999;13:460-468.
36. Baldini L, Fracchiolla NS, Cro LM, et al. Frequent p53 gene involvement in splenic B-cell leukemia/ lymphomas of possible marginal zone origin. Blood. 1994;84;270-278.
37. Baldini L, Guffanti A, Cro L, et al. Poor prognosis in non-villous splenic marginal zone cell lymphoma is associated with p53 mutations. Br J Haematol. 1997;99:375-378.
38. Lloret E, Mollejo M, Mateo MS, et al. Splenic marginal zone lymphoma with increased number of blasts: an aggressive variant? Hum Pathol. 1999; 30:1153-1160.
39. Sol Mateo M, Mollejo M, Villuendas R, et al. Analysis of the frequency of microsatellite instability and p53 gene mutation in splenic marginal zone and MALT lymphomas. Mol Pathol. 1998;51:262-267.